REMEGEN Shares Surge Over 8% on Proposed A-Share Buyback and Positive Outlook for Telitacicept

Stock News07-20 14:26

REMEGEN (HKEX: 09995) shares rose more than 8% in Hong Kong trading.

At the time of writing, the stock was up 8.33% to HK$82.6, with a turnover of HK$372 million.

The company announced a plan last night to repurchase its A-shares via centralized bidding, using no less than 25 million yuan and no more than 50 million yuan of its own funds and/or raised capital.

The repurchased shares are intended for an employee stock ownership plan or equity incentive scheme.

This development follows the recent inclusion of the company's self-developed, globally first-in-class BLyS/APRIL dual-target novel fusion protein drug, Telitacicept (for injection, sterile powder: 80mg), in the National Essential Medicines List (2026 Edition).

It is also noteworthy that in June this year, the company announced that Telitacicept had received approval for two new indications: IgA nephropathy and Sjögren's syndrome.

Analysts believe this move will further unlock the commercial potential of Telitacicept.

Looking ahead, the company possesses multiple cutting-edge technology platforms including fusion proteins, bispecific antibodies, antibody-drug conjugates (ADCs), and T-cell engagers.

New products such as RC278 (a CDCP1-targeting ADC) and RC288 (a PSMA/B7H3 bispecific ADC) are progressively advancing from research into clinical stages, leading to a positive long-term growth outlook for the company.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188280575?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-20 14:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188280575","market":"sg","top_or_hot":-1,"title":"REMEGEN Shares Surge Over 8% on Proposed A-Share Buyback and Positive Outlook for Telitacicept","media":"Stock News","content":"<p><b>REMEGEN</b> (<b>HKEX: 09995</b>) shares rose more than 8% in Hong Kong trading.<br><br>At the time of writing, the stock was up 8.33% to HK$82.6, with a turnover of HK$372 million.<br><br>The company announced a plan last night to repurchase its A-shares via centralized bidding, using no less than 25 million yuan and no more than 50 million yuan of its own funds and/or raised capital.<br><br>The repurchased shares are intended for an employee stock ownership plan or equity incentive scheme.<br><br>This development follows the recent inclusion of the company's self-developed, globally first-in-class BLyS/APRIL dual-target novel fusion protein drug, Telitacicept (for injection, sterile powder: 80mg), in the <i>National Essential Medicines List (2026 Edition)</i>.<br><br>It is also noteworthy that in June this year, the company announced that Telitacicept had received approval for two new indications: IgA nephropathy and Sjögren's syndrome.<br><br>Analysts believe this move will further unlock the commercial potential of Telitacicept.<br><br>Looking ahead, the company possesses multiple cutting-edge technology platforms including fusion proteins, bispecific antibodies, antibody-drug conjugates (ADCs), and T-cell engagers.<br><br>New products such as RC278 (a CDCP1-targeting ADC) and RC288 (a PSMA/B7H3 bispecific ADC) are progressively advancing from research into clinical stages, leading to a positive long-term growth outlook for the company.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>REMEGEN Shares Surge Over 8% on Proposed A-Share Buyback and Positive Outlook for Telitacicept</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nREMEGEN Shares Surge Over 8% on Proposed A-Share Buyback and Positive Outlook for Telitacicept\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-20 14:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>REMEGEN</b> (<b>HKEX: 09995</b>) shares rose more than 8% in Hong Kong trading.<br><br>At the time of writing, the stock was up 8.33% to HK$82.6, with a turnover of HK$372 million.<br><br>The company announced a plan last night to repurchase its A-shares via centralized bidding, using no less than 25 million yuan and no more than 50 million yuan of its own funds and/or raised capital.<br><br>The repurchased shares are intended for an employee stock ownership plan or equity incentive scheme.<br><br>This development follows the recent inclusion of the company's self-developed, globally first-in-class BLyS/APRIL dual-target novel fusion protein drug, Telitacicept (for injection, sterile powder: 80mg), in the <i>National Essential Medicines List (2026 Edition)</i>.<br><br>It is also noteworthy that in June this year, the company announced that Telitacicept had received approval for two new indications: IgA nephropathy and Sjögren's syndrome.<br><br>Analysts believe this move will further unlock the commercial potential of Telitacicept.<br><br>Looking ahead, the company possesses multiple cutting-edge technology platforms including fusion proteins, bispecific antibodies, antibody-drug conjugates (ADCs), and T-cell engagers.<br><br>New products such as RC278 (a CDCP1-targeting ADC) and RC288 (a PSMA/B7H3 bispecific ADC) are progressively advancing from research into clinical stages, leading to a positive long-term growth outlook for the company.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2148510915.USD","symbol_name":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","start_time":0,"source_url":"","article_id":"1188280575","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188280575","pubTimestamp":1784528783,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"REMEGEN (HKEX: 09995) shares rose more than 8% in Hong Kong trading.At the time of writing, the stock was up 8.33% to HK$82.6, with a turnover of HK$372 million.The company announced a plan last...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159982":"中证500","399300":"沪深300","688331":"荣昌生物","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","09995":"荣昌生物","KCAI":"KraneShares China Alpha Index ETF","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","BK1583":"高瓴概念","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","BK1161":"生物科技","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK0239":"医药制造","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1574":"生物医药B类股"},"translate_title":"由于 A 股回购提议和 Telitacicept 前景乐观，REMEGEN 股价飙升超过 8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159982":1,"399300":1,"688331":1,"09995":1,"VXUS":1,"KCAI":1},"content_text":"REMEGEN (HKEX: 09995) shares rose more than 8% in Hong Kong trading.At the time of writing, the stock was up 8.33% to HK$82.6, with a turnover of HK$372 million.The company announced a plan last night to repurchase its A-shares via centralized bidding, using no less than 25 million yuan and no more than 50 million yuan of its own funds and/or raised capital.The repurchased shares are intended for an employee stock ownership plan or equity incentive scheme.This development follows the recent inclusion of the company's self-developed, globally first-in-class BLyS/APRIL dual-target novel fusion protein drug, Telitacicept (for injection, sterile powder: 80mg), in the National Essential Medicines List (2026 Edition).It is also noteworthy that in June this year, the company announced that Telitacicept had received approval for two new indications: IgA nephropathy and Sjögren's syndrome.Analysts believe this move will further unlock the commercial potential of Telitacicept.Looking ahead, the company possesses multiple cutting-edge technology platforms including fusion proteins, bispecific antibodies, antibody-drug conjugates (ADCs), and T-cell engagers.New products such as RC278 (a CDCP1-targeting ADC) and RC288 (a PSMA/B7H3 bispecific ADC) are progressively advancing from research into clinical stages, leading to a positive long-term growth outlook for the company.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188280575","isCrawlerRequest":true}